WolverHeme Happy Hour

Author: Bernard Marini, Anthony Perissinotti, et al.

Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
Be a guest on this podcast

Language: en

Genres: Health & Fitness, Medicine

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

Bispecifics ate CAR-T's lunch: a multiple myeloma debate
Episode 48
Thursday, 11 June, 2026

In this episode, Bernie and Anthony are joined by Myeloma Man Manni Mohyuddin, MD to discuss the debate surrounding the treatment of first relapse in multiple myeloma. Should we be using CAR-T? Bispecifics? How does the new mezigdomide data from ASCO 2026 inform our practice? Listen in for a spicy discussion!Articles discussed:Nature Reviews Commentary: https://www.nature.com/articles/s41571-026-01159-6CARTITUDE-4: https://www.nature.com/articles/s41571-026-01159-6MajesTEC-3: https://www.nejm.org/doi/full/10.1056/NEJMoa2514663 MajesTEC-9: https://www.nejm.org/doi/abs/10.1056/NEJMoa2603870 Control arms in multiple myeloma trials: https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2026020329/567836/Improving-Control-Arms-in-2026-U-S-Myeloma-TrialsPredictors for CAR T cell therapy-associated immune-related adverse events? https://pubmed.ncbi.nlm.nih.gov/41540109/Dex prophylaxis for lymphocytosis: https://ashpublications.org/bloodadvances/article/10/10/3629/567462/Dexamethasone-prophylaxis-for-excessive-lymphocyteMezi-KD vs. KD ASCO 2026: https://ascopubs.org/doi/10.1200/JCO.2026.44.17_suppl.LBA7506